CLAIMS

1. A compound of formula (I), or a salt, prodrug, solvate, isotopologue, or stereoisomer thereof:



(I),

wherein:

A is 

,

wherein * indicates the bond between L and $N(R^1)(R^2)$;

L is 

;

R^{a1} and R^{a2} are each independently selected from the group consisting of H, halogen, C_1-C_6 alkoxy, and C_1-C_6 alkyl,

or R^{a1} and R^{a2} may combine to form a carbonyl (C=O);

R^{b1} and R^{b2} are each independently selected from the group consisting of H and C_1-C_6 alkyl;

R^1 and R^2 are each independently selected from the group consisting of optionally substituted C_1-C_8 alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted C_2-C_8 heterocycloalkyl, optionally substituted C_2-C_8 alkenyl, and optionally substituted C_2-C_8 alkynyl,

wherein R^1 and R^2 are not identical, and

wherein one of R^1 and R^2 may combine with one of R^{a1}, R^{a2}, R^{b1}, and R^{b2} to form an optionally substituted C_2-C_8 heterocyclyl,

with the proviso that, if one of R^1 and R^2 combines with R^{b1} or R^{b2} to form a 5 membered ring and R^5 is F, then at least one of R^4, R^6, and R^7 is not H, or if one of R^1 and R^2 combine with R^{b1} or R^{b2} to form a stereocenter then the compound consists essentially of one stereoisomer;

R^3 is selected from the group consisting of H, halogen, optionally substituted C_1-C_8 alkyl, optionally substituted benzyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted

C_2-C_8 alkenyl, and optionally substituted C_2-C_8 alkynyl;

R^4, R^5, R^6, and R^7 are each independently selected from the group consisting of H, F, Cl, Br, I, OR^A, $N(R^A)(R^B)$, SR^A, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted benzyl, optionally substituted phenyl, and optionally substituted C_2-C_9 heteroaryl,

wherein at least one of R^4, R^5, R^6, and R^7 is F;

each occurrence of R^A is independently selected from the group consisting of H, C_1-C_6 haloalkyl, C_2-C_6 alkynyl, C_1-C_6 alkyl, -C(=O)C_1-C_6 alkyl, -C(=O)C_6-C_{10} aryl, -C(=O)NH(C_1-C_6 alkyl), -C(=O)NH(C_6-C_{10} aryl), -C(=O)N(C_1-C_6 alkyl)$_2$, -C(=O)N(C_1-C_6 alkyl)(C_6-C_{10} aryl), -C(=O)O(C_1-C_6 alkyl), -C(=O)O(C_6-C_{10} aryl), -P(=O)(O(C_1-C_6 alkyl))$_2$, -P(=O)(O(C_1-C_6 alkyl))(OH), -P(=O)(OH)$_2$, -S(=O)$_2$O(C_6-C_{10} aryl), -S(=O)$_2$O(C_1-C_6 alkyl), -S(=O)$_2$O(C_6-C_{10} aryl), -S(=O)$_2$NH(C_1-C_6 alkyl), -S(=O)$_2$NH(C_6-C_{10} aryl), -S(=O)$_2$N(C_1-C_6 alkyl)(C_1-C_6 alkyl), and -S(=O)$_2$N(C_1-C_6 alkyl)(C_6-C_{10} aryl);

each occurrence of R^B is independently selected from the group consisting of H, C_1-C_6 alkyl, C_1-C_3 haloalkyl, C_2-C_6 alkenyl, benzyl, naphthyl, C_2-C_9 heteroaryl, and phenyl;

wherein the isotopologue does not comprise F^{18} in R^1 or R^2; and

wherein the compound of formula (I) is not selected from the group consisting of:

N-ethyl-N-(2-(4-fluoro-1H-indol-3-yl)ethyl)propan-1-amine;

N-ethyl-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)propan-1-amine;

N-ethyl-N-(2-(6-fluoro-1H-indol-3-yl)ethyl)propan-1-amine;

N-ethyl-N-(2-(7-fluoro-1H-indol-3-yl)ethyl)propan-1-amine;

N-ethyl-2-(4-fluoro-1H-indol-3-yl)-N-methylethan-1-amine;

N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine;

N-ethyl-2-(6-fluoro-1H-indol-3-yl)-N-methylethan-1-amine;

N-ethyl-2-(7-fluoro-1H-indol-3-yl)-N-methylethan-1-amine;

(R)-4-fluoro-3-((1-(methyl-d3)pyrrolidin-2-yl)methyl-d2)-1H-indole;

(R)-4-fluoro-3-((1-(methyl-d3)pyrrolidin-2-yl)methyl)-1H-indole;

(R)-4-fluoro-3-(pyrrolidin-2-ylmethyl-d2)-1H-indole; and

(S)-4-fluoro-3-((1-(methyl-d3)pyrrolidin-2-yl)methyl-d2)-1H-indole.

2. The compound of claim 1, wherein R^1 is optionally substituted C_1-C_3 alkyl and R^2 is selected from the group consisting of optionally substituted, branched C_3-C_8 alkyl and optionally substituted C_3-C_8 cycloalkyl, optionally wherein R^1 is selected from the group

consisting of methyl, allyl, and *n*-propyl.

3. The compound of any one of claims 1-2, wherein:

(a) R^2 is optionally substituted, branched C_3-C_8 alkyl, optionally wherein R^2 is selected from the group consisting of *iso*-propyl, *sec*-butyl, *iso*-butyl, 1,2-dimethylpropyl, methylallyl, and 2-methylallyl;

(b) R^2 is optionally substituted C_3-C_8 cycloalkyl, optionally wherein R^2 is selected from the group consisting of cyclopropyl and cyclobutyl.

4. The compound of claim 1, wherein each of R^1 and R^2 are independently selected from the group consisting of methyl, ethyl, *n*-propyl, 1,2-dimethylpropyl, *iso*-propyl, *sec*-butyl, *iso*-butyl, *n*-butyl, cyclopropyl, cyclopropylmethyl, methylcyclopropyl, cyclopropylethyl, 2-cyclopropyleth-2-yl, cyclobutyl, 2-thietanyl, 3-thietanyl, allyl, methylallyl, 2-methylallyl, 3-methylallyl, propargyl, cyanomethyl, 2-hydroxyethyl, and 2-methoxyethyl.

5. The compound of any one of claims 1-4, wherein R^3 is H.

6. The compound of any one of claims 1-5, wherein at least one of the following applies:

(a) R^4 is F and each of R^5, R^6, and R^7 is H;

(b) R^5 is F, and each of R^4, R^6, and R^7 is H;

(c) R^7 is F, and each of R^4, R^5, and R^6 is H;

(d) each of R^4 and R^5 is F, and each of R^6 and R^7 is H;

(e) each of R^4 and R^6 is F, and each of R^5 and R^7 is H;

(f) each of R^4 and R^7 is F, and each of R^5 and R^6 is H;

(g) each of R^5 and R^6 is F, and each of R^4 and R^7 is H;

(h) each of R^5 and R^7 is F, and each of R^4 and R^6 is H;

(i) each of R^6 and R^7 is F, and each of R^4 and R^5 is H;

(j) R^5 is OMe, R^7 is F, and each of R^4 and R^6 is H;

(k) each of R^5, R^6, and R^7 are F, and R^4 is H.

7. The compound of any one of claims 1-5, wherein R^5 is selected from the group consisting of OR^A, $N(R^A)(R^B)$, and SR^A.

8. The compound of any one of claims 1-5, wherein R^5 is selected from the group consisting of H, F, Cl, OMe, OH, and Me, optionally wherein R^5 is OMe or F.

9. The compound of any one of claims 1-5 and 7-8, wherein R^6 is selected from the group consisting of H, F, Me, Cl, and/or wherein R^7 is selected from the group consisting of H, F, Cl, Br, and Me.

10. The compound of any one of claims 1-5 and 7-9, wherein each of R^4 and R^6 is H.

11. The compound of any one of claims 1-10, wherein L is selected from the group consisting of , , and , optionally wherein L is ..

12. The compound of any one of claims 1-10, wherein A is selected from the group consisting of:

, , , , , and , and

wherein:

R^{c1}, R^{c2}, R^{d1}, R^{d2}, R^{e1}, and R^{e2}, if present, are each independently selected from the group consisting of H, C_1-C_3 alkyl, and C_1-C_3 haloalkyl.

13. The compound of any one of claims 1-10 and 12, wherein each of R^{a1}, R^{a2}, R^{b1}, R^{b2}, R^{c1}, R^{c2}, R^{d1}, R^{d2}, R^{e1}, R^{e2}, R^{f1}, and R^{f2}, if present, is H.

14. The compound of any one of claims 1-13, wherein A is selected from the group consisting of:













15. The compound of any one of claims 1-14, which is selected from the group consisting of:

N-ethyl-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)propan-2-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-methylpropan-2-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-methylbutan-2-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-isopropylpropan-1-amine;

N-(2-(5,6-difluoro-1H-indol-3-yl)ethyl)-N-ethylpropan-1-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-methylprop-2-en-1-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-isopropylprop-2-en-1-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-methylpropan-1-amine;

N-allyl-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)cyclobutanamine;

N-allyl-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)butan-2-amine;

2-((2-(5-fluoro-1H-indol-3-yl)ethyl)(isopropyl)amino)acetonitrile;

5,6-difluoro-3-(1-methylpyrrolidin-3-yl)-1H-indole;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-methylthietan-3-amine;

N-(2-(4,5-difluoro-1H-indol-3-yl)ethyl)-N-ethylpropan-1-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-propylbutan-2-amine;

7-fluoro-3-(1-methylpyrrolidin-3-yl)-1H-indole;

2-(ethyl(propyl)amino)-1-(5-fluoro-1H-indol-3-yl)ethan-1-one;

2-(ethyl(methyl)amino)-1-(5-fluoro-1H-indol-3-yl)ethan-1-one;

(S)-5-fluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;

(R)-5-fluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;

5-fluoro-3-(1-methylazetidin-3-yl)-1H-indole;

N-ethyl-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)butan-2-amine;

N-ethyl-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)cyclobutanamine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-isopropylbutan-2-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-propylcyclobutanamine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-isopropylprop-2-yn-1-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-propylprop-2-en-1-amine;

N-ethyl-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)prop-2-en-1-amine;

N-(2-(6-chloro-5-fluoro-1H-indol-3-yl)ethyl)-N-ethylpropan-1-amine;

1-cyclopropyl-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-methylethan-1-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N,2-dimethylpropan-1-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-isopropylcyclobutanamine;

N-ethyl-N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)propan-1-amine;

N-(2-(4-fluoro-1H-indol-3-yl)ethyl)-N-methylpropan-1-amine;

N-(2-(4-fluoro-1H-indol-3-yl)ethyl)-N-methylpropan-2-amine;

N-ethyl-N-(2-(4-fluoro-1H-indol-3-yl)ethyl)propan-2-amine;

N-(2-(4-fluoro-1H-indol-3-yl)ethyl)-N,2-dimethylpropan-1-amine;

N-(2-(4-fluoro-1H-indol-3-yl)ethyl)-N-methylcyclobutanamine;

N-(2-(4-fluoro-1H-indol-3-yl)ethyl)-N-methylprop-2-en-1-amine;

N-(2-(4-fluoro-1H-indol-3-yl)ethyl)-N-isopropyl-2-methylpropan-1-amine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-methylcyclobutanamine;

N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-isopropyl-2-methylpropan-1-amine;

N-(2-(7-fluoro-1H-indol-3-yl)ethyl)-N-methylpropan-1-amine;

N-(2-(7-fluoro-1H-indol-3-yl)ethyl)-N-methylpropan-2-amine;

N-ethyl-N-(2-(7-fluoro-1H-indol-3-yl)ethyl)propan-2-amine;

N-(2-(7-fluoro-1H-indol-3-yl)ethyl)-N,2-dimethylpropan-1-amine;

N-(2-(7-fluoro-1H-indol-3-yl)ethyl)-N-methylcyclobutanamine;

N-(2-(7-fluoro-1H-indol-3-yl)ethyl)-N-methylprop-2-en-1-amine;

N-(2-(7-fluoro-1H-indol-3-yl)ethyl)-N-isopropyl-2-methylpropan-1-amine;

2-(5,6-difluoro-1H-indol-3-yl)-N-ethyl-N-methylethan-1-amine;

N-(2-(5,6-difluoro-1H-indol-3-yl)ethyl)-N-methylpropan-1-amine;

N-(2-(5,6-difluoro-1H-indol-3-yl)ethyl)-N-methylpropan-2-amine;

N-(2-(5,6-difluoro-1H-indol-3-yl)ethyl)-N-ethylpropan-2-amine;

N-(2-(5,6-difluoro-1H-indol-3-yl)ethyl)-N,2-dimethylpropan-1-amine;

N-(2-(5,6-difluoro-1H-indol-3-yl)ethyl)-N-methylcyclobutanamine;

N-(2-(5,6-difluoro-1H-indol-3-yl)ethyl)-N-methylprop-2-en-1-amine;

N-(2-(5,6-difluoro-1H-indol-3-yl)ethyl)-N-isopropyl-2-methylpropan-1-amine;
2-(5,7-difluoro-1H-indol-3-yl)-N-ethyl-N-methylethan-1-amine;
N-(2-(5,7-difluoro-1H-indol-3-yl)ethyl)-N-methylpropan-1-amine;
N-(2-(5,7-difluoro-1H-indol-3-yl)ethyl)-N-methylpropan-2-amine;
N-(2-(5,7-difluoro-1H-indol-3-yl)ethyl)-N-ethylpropan-1-amine;
N-(2-(5,7-difluoro-1H-indol-3-yl)ethyl)-N-ethylpropan-2-amine;
N-(2-(5,7-difluoro-1H-indol-3-yl)ethyl)-N,2-dimethylpropan-1-amine;
N-(2-(5,7-difluoro-1H-indol-3-yl)ethyl)-N-methylcyclobutanamine;
N-(2-(5,7-difluoro-1H-indol-3-yl)ethyl)-N-methylprop-2-en-1-amine;
N-(2-(5,7-difluoro-1H-indol-3-yl)ethyl)-N-isopropyl-2-methylpropan-1-amine;
2-(6,7-difluoro-1H-indol-3-yl)-N-ethyl-N-methylethan-1-amine;
N-(2-(6,7-difluoro-1H-indol-3-yl)ethyl)-N-methylpropan-1-amine;
N-(2-(6,7-difluoro-1H-indol-3-yl)ethyl)-N-methylpropan-2-amine;
N-(2-(6,7-difluoro-1H-indol-3-yl)ethyl)-N-ethylpropan-1-amine;
N-(2-(6,7-difluoro-1H-indol-3-yl)ethyl)-N-ethylpropan-2-amine;
N-(2-(6,7-difluoro-1H-indol-3-yl)ethyl)-N,2-dimethylpropan-1-amine;
N-(2-(6,7-difluoro-1H-indol-3-yl)ethyl)-N-methylcyclobutanamine;
N-(2-(6,7-difluoro-1H-indol-3-yl)ethyl)-N-methylprop-2-en-1-amine;
N-(2-(6,7-difluoro-1H-indol-3-yl)ethyl)-N-isopropyl-2-methylpropan-1-amine;
N-ethyl-2-(7-fluoro-5-methoxy-1H-indol-3-yl)-N-methylethan-1-amine;
N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-methylpropan-1-amine;
N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-methylpropan-2-amine;
N-ethyl-N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)propan-2-amine;
N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N,2-dimethylpropan-1-amine;
N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-methylcyclobutanamine;
N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-methylprop-2-en-1-amine;
N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-isopropyl-2-methylpropan-1-amine;
3-(2-(ethyl(methyl)amino)ethyl)-7-fluoro-1H-indol-5-ol;
7-fluoro-3-(2-(methyl(propyl)amino)ethyl)-1H-indol-5-ol;
7-fluoro-3-(2-(isopropyl(methyl)amino)ethyl)-1H-indol-5-ol;
3-(2-(ethyl(propyl)amino)ethyl)-7-fluoro-1H-indol-5-ol;
3-(2-(ethyl(isopropyl)amino)ethyl)-7-fluoro-1H-indol-5-ol;
7-fluoro-3-(2-(isobutyl(methyl)amino)ethyl)-1H-indol-5-ol;

3-(2-(cyclobutyl(methyl)amino)ethyl)-7-fluoro-1H-indol-5-ol;

3-(2-(allyl(methyl)amino)ethyl)-7-fluoro-1H-indol-5-ol;

7-fluoro-3-(2-(isobutyl(isopropyl)amino)ethyl)-1H-indol-5-ol;

4-fluoro-3-(1-methylpyrrolidin-3-yl)-1H-indole;

6-fluoro-3-(1-methylpyrrolidin-3-yl)-1H-indole;

4,5-difluoro-3-(1-methylpyrrolidin-3-yl)-1H-indole;

4,6-difluoro-3-(1-methylpyrrolidin-3-yl)-1H-indole;

5,7-difluoro-3-(1-methylpyrrolidin-3-yl)-1H-indole;

6,7-difluoro-3-(1-methylpyrrolidin-3-yl)-1H-indole;

4-fluoro-3-(1-methylpiperidin-3-yl)-1H-indole;

5-fluoro-3-(1-methylpiperidin-3-yl)-1H-indole;

6-fluoro-3-(1-methylpiperidin-3-yl)-1H-indole;

7-fluoro-3-(1-methylpiperidin-3-yl)-1H-indole;

4,5-difluoro-3-(1-methylpiperidin-3-yl)-1H-indole;

4,6-difluoro-3-(1-methylpiperidin-3-yl)-1H-indole;

5,6-difluoro-3-(1-methylpiperidin-3-yl)-1H-indole;

5,7-difluoro-3-(1-methylpiperidin-3-yl)-1H-indole;

6,7-difluoro-3-(1-methylpiperidin-3-yl)-1H-indole;

4-fluoro-3-(methylprolyl)-1H-indole;

6-fluoro-3-(methylprolyl)-1H-indole;

7-fluoro-3-(methylprolyl)-1H-indole;

4,5-difluoro-3-(methylprolyl)-1H-indole;

4,6-difluoro-3-(methylprolyl)-1H-indole;

5,6-difluoro-3-(methylprolyl)-1H-indole;

5,7-difluoro-3-(methylprolyl)-1H-indole;

6,7-difluoro-3-(methylprolyl)-1H-indole;

4-fluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;

6-fluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;

7-fluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;

4,5-difluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;

4,6-difluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;

5,6-difluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;

5,7-difluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;

6,7-difluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;
N-(sec-butyl)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)cyclobutanamine;
N-(cyclopropylmethyl)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)propan-2-amine;
N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-methylcyclopropanamine;
N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-propylcyclopropanamine;
N-(2-(7-fluoro-1H-indol-3-yl)ethyl)-N-propylcyclobutanamine;
N-(2-(7-fluoro-1H-indol-3-yl)ethyl)-N-propylbutan-2-amine;
N-ethyl-N-methyl-2-(5,6,7-trifluoro-1H-indol-3-yl)ethan-1-amine;
N-ethyl-N-(2-(5,6,7-trifluoro-1H-indol-3-yl)ethyl)propan-1-amine;
N-ethyl-N-(2-(7-fluoro-5-methyl-1H-indol-3-yl)ethyl)propan-1-amine;
N-ethyl-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)cyclopropanamine;
N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-isopropylcyclopropanamine;
N-ethyl-2-(5-fluoro-7-methyl-1H-indol-3-yl)-N-methylethan-1-amine;
N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N,3-dimethylbutan-2-amine;
N-(sec-butyl)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)cyclopropanamine;
N-cyclopropyl-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)cyclobutanamine;
2-(7-bromo-5-fluoro-1H-indol-3-yl)-N-ethyl-N-methylethan-1-amine;
N-ethyl-2-(5-fluoro-6-methyl-1H-indol-3-yl)-N-methylethan-1-amine;
N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-(prop-2-yn-1-yl)butan-2-amine;
2-(sec-butyl(2-(5-fluoro-1H-indol-3-yl)ethyl)amino)acetonitrile;
N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-methylbut-3-en-2-amine;
2-(5-chloro-6-fluoro-1H-indol-3-yl)-N-ethyl-N-methylethan-1-amine;
N-(2-(7-fluoro-1H-indol-3-yl)ethyl)-N-propylprop-2-yn-1-amine;
2-((2-(7-fluoro-1H-indol-3-yl)ethyl)(propyl)amino)acetonitrile;
2-(7-chloro-5-fluoro-1H-indol-3-yl)-N-ethyl-N-methylethan-1-amine;
(R)-3-((1-ethylpyrrolidin-2-yl)methyl)-5-fluoro-1H-indole;
(R)-5-fluoro-3-(pyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-fluoro-3-((1-propylpyrrolidin-2-yl)methyl)-1H-indole;
(R)-5,6-difluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;
(R)-7-fluoro-3-((1-methylpyrrolidin-2-yl)methyl)-1H-indole;
2-(ethyl(propyl)amino)-1-(5-fluoro-1H-indol-3-yl)ethan-1-one;
N-isopropyl-N-(2-(5,6,7-trifluoro-1H-indol-3-yl)ethyl)propan-1-amine;
N-methyl-N-(2-(5,6,7-trifluoro-1H-indol-3-yl)ethyl)butan-2-amine;

N-methyl-N-(2-(5,6,7-trifluoro-1H-indol-3-yl)ethyl)cyclobutanamine;
N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-isopropylpropan-1-amine;
N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-methylbutan-2-amine;
N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-methylbut-3-en-2-amine;
N-(2-(5,6-difluoro-1H-indol-3-yl)ethyl)-N-methylbut-3-en-2-amine;
N-(2-(6,7-difluoro-1H-indol-3-yl)ethyl)-N-methylbut-3-en-2-amine;
N-(2-(5,7-difluoro-1H-indol-3-yl)ethyl)-N-methylbut-3-en-2-amine;
N-methyl-N-(2-(5,6,7-trifluoro-1H-indol-3-yl)ethyl)but-3-en-2-amine;
3-(((2R)-1-(sec-butyl)pyrrolidin-2-yl)methyl)-5-fluoro-1H-indole;
(R)-5-fluoro-3-((1-isopropylpyrrolidin-2-yl)methyl)-1H-indole;
(R)-3-((1-cyclobutylpyrrolidin-2-yl)methyl)-5-fluoro-1H-indole;
(R)-3-((1-cyclopropylpyrrolidin-2-yl)methyl)-5-fluoro-1H-indole;
(R)-3-((1-allylpyrrolidin-2-yl)methyl)-5-fluoro-1H-indole;
3-(((2R)-1-(but-3-en-2-yl)pyrrolidin-2-yl)methyl)-5-fluoro-1H-indole;
(R)-5-fluoro-3-((1-(prop-2-yn-1-yl)pyrrolidin-2-yl)methyl)-1H-indole;
3-(((2R)-1-(sec-butyl)pyrrolidin-2-yl)methyl)-5,6,7-trifluoro-1H-indole;
(R)-5,6,7-trifluoro-3-((1-isopropylpyrrolidin-2-yl)methyl)-1H-indole;
(R)-3-((1-cyclobutylpyrrolidin-2-yl)methyl)-5,6,7-trifluoro-1H-indole;
(R)-3-((1-cyclopropylpyrrolidin-2-yl)methyl)-5,6,7-trifluoro-1H-indole;
(R)-3-((1-allylpyrrolidin-2-yl)methyl)-5,6,7-trifluoro-1H-indole;
3-(((2R)-1-(but-3-en-2-yl)pyrrolidin-2-yl)methyl)-5,6,7-trifluoro-1H-indole;
(R)-5,6,7-trifluoro-3-((1-(prop-2-yn-1-yl)pyrrolidin-2-yl)methyl)-1H-indole;
3-(((2R)-1-(sec-butyl)pyrrolidin-2-yl)methyl)-7-fluoro-5-methoxy-1H-indole;
(R)-7-fluoro-3-((1-isopropylpyrrolidin-2-yl)methyl)-5-methoxy-1H-indole;
(R)-3-((1-cyclobutylpyrrolidin-2-yl)methyl)-7-fluoro-5-methoxy-1H-indole;
(R)-3-((1-cyclopropylpyrrolidin-2-yl)methyl)-7-fluoro-5-methoxy-1H-indole;
(R)-3-((1-allylpyrrolidin-2-yl)methyl)-7-fluoro-5-methoxy-1H-indole;
3-(((2R)-1-(but-3-en-2-yl)pyrrolidin-2-yl)methyl)-7-fluoro-5-methoxy-1H-indole; and
(R)-7-fluoro-5-methoxy-3-((1-(prop-2-yn-1-yl)pyrrolidin-2-yl)methyl)-1H-indole.

16. A compound of formula (II), or a salt, prodrug, solvate, isotopologue, or stereoisomer thereof:



(II),

wherein:

R^3 is selected from the group consisting of H, optionally substituted C_1-C_8 alkyl, optionally substituted benzyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted C_2-C_8 alkenyl, and optionally substituted C_2-C_8 alkynyl;

R^4, R^5, R^6, and R^7 are each independently selected from the group consisting of H, F, Cl, Br, I, OR^A, $N(R^A)(R^B)$, SR^A, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted benzyl, optionally substituted phenyl, and optionally substituted C_2-C_9 heteroaryl,

wherein at least one of R^4, R^5, R^6, and R^7 is F;

R^8 and R^9 are each independently selected from the group consisting of optionally substituted C_1-C_8 alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted C_2-C_8 alkenyl, and optionally substituted C_2-C_8 alkynyl;

R^{10} is selected from the group consisting of H, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted benzyl, optionally substituted phenyl, and optionally substituted C_2-C_9 heteroaryl;

R^{f1} and R^{f2} are each independently selected from the group consisting of H and C_1-C_6 alkyl;

each occurrence of R^A is independently selected from the group consisting of H, C_1-C_6 haloalkyl, C_2-C_6 alkynyl, C_1-C_6 alkyl, -C(=O)C_1-C_6 alkyl, -C(=O)C_6-C_{10} aryl, -C(=O)NH(C_1-C_6 alkyl), -C(=O)NH(C_6-C_{10} aryl), -C(=O)N(C_1-C_6 alkyl)$_2$, -C(=O)N(C_1-C_6 alkyl)(C_6-C_{10} aryl), -C(=O)O(C_1-C_6 alkyl), -C(=O)O(C_6-C_{10} aryl), -P(=O)(O(C_1-C_6 alkyl))$_2$, -P(=O)(O(C_1-C_6 alkyl))(OH), -P(=O)(OH)$_2$, -S(=O)$_2$O(C_6-C_{10} aryl), -S(=O)$_2$O(C_1-C_6 alkyl), -S(=O)$_2$O(C_6-C_{10} aryl), -S(=O)$_2$NH(C_1-C_6 alkyl), -S(=O)$_2$NH(C_6-C_{10} aryl), -S(=O)$_2$N(C_1-C_6 alkyl)(C_1-C_6 alkyl), and -S(=O)$_2$N(C_1-C_6 alkyl)(C_6-C_{10} aryl); and

each occurrence of R^B is independently selected from the group consisting of H, C_1-C_6 alkyl, C_1-C_3 haloalkyl, C_2-C_6 alkenyl, benzyl, naphthyl, C_2-C_9 heteroaryl, and phenyl.

17. The compound of claim 16, wherein at least one of the following applies:

(a) R^3 is H;

(b) R^8 and R^9 are each independently selected from the group consisting of methyl, ethyl, and *n*-propyl;

(c) R^{10} is H;

(d) R^{f1} and R^{f2} are H.

18. The compound of claim 16 or 17, wherein:

(a) R^4 is F, and each of R^5, R^6, and R^7 is H;

(b) R^5 is F, and each of R^4, R^6, and R^7 is H;

(c) R^6 is F, and each of R^4, R^5, and R^7 is H;

(d) R^7 is F, and each of R^4, R^5, and R^6 is H;

(e) each of R^4 and R^5 is F, and each of R^6 and R^7 is H;

(f) each of R^4 and R^6 is F, and each of R^5 and R^7 is H;

(g) each of R^4 and R^7 is F, and each of R^5 and R^6 is H;

(h) each of R^5 and R^6 is F, and each of R^4 and R^7 is H;

(i) each of R^5 and R^7 is F, and each of R^4 and R^6 is H; or

(j) each of R^6 and R^7 is F, and each of R^4 and R^5 is H.

19. The compound of any one of claims 16-18, which is selected from the group consisting of:

2-(ethyl(propyl)amino)-1-(5-fluoro-1H-indol-3-yl)ethan-1-one;

2-(ethyl(methyl)amino)-1-(5-fluoro-1H-indol-3-yl)ethan-1-one;

2-(dimethylamino)-1-(4-fluoro-1H-indol-3-yl)ethan-1-one;

2-(dimethylamino)-1-(5-fluoro-1H-indol-3-yl)ethan-1-one;

2-(dimethylamino)-1-(6-fluoro-1H-indol-3-yl)ethan-1-one;

2-(dimethylamino)-1-(7-fluoro-1H-indol-3-yl)ethan-1-one;

1-(4,5-difluoro-1H-indol-3-yl)-2-(dimethylamino)ethan-1-one;

1-(4,6-difluoro-1H-indol-3-yl)-2-(dimethylamino)ethan-1-one;

1-(5,6-difluoro-1H-indol-3-yl)-2-(dimethylamino)ethan-1-one;

1-(5,7-difluoro-1H-indol-3-yl)-2-(dimethylamino)ethan-1-one; and

1-(6,7-difluoro-1H-indol-3-yl)-2-(dimethylamino)ethan-1-one.

20. A compound of formula (III), or a salt, prodrug, solvate, isotopologue, or stereoisomer thereof:



(III),

wherein:

R^8 and R^9 are each independently selected from the group consisting of optionally substituted C_1-C_8 alkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted C_2-C_8 alkenyl, and optionally substituted C_2-C_8 alkynyl;

R^{10} is selected from the group consisting of H, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted benzyl, optionally substituted phenyl, and optionally substituted C_2-C_9 heteroaryl;

R^{11} and R^{12} are each independently selected from the group consisting of H, F, Cl, Br, I, OR^A, $N(R^A)(R^B)$, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted benzyl, optionally substituted phenyl, and optionally substituted C_2-C_9 heteroaryl;

R^{13} is selected from the group consisting of H, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 alkenyl, optionally substituted C_1-C_6 alkynyl, optionally substituted C_1-C_3 haloalkyl, optionally substituted benzyl, optionally substituted phenyl, and optionally substituted C_2-C_9 heteroaryl;

R^{f1} and R^{f2} are each independently selected from the group consisting of H and C_1-C_6 alkyl;

R^{g1} and R^{g2} are each independently selected from the group consisting of H and C_1-C_6 alkyl;

each occurrence of R^A is independently selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 haloalkyl, -C(=O)C_1-C_6 alkyl, -C(=O)C_6-C_{10} aryl, -C(=O)NH(C_1-C_6 alkyl), -C(=O)NH(C_6-C_{10} aryl), -C(=O)N(C_1-C_6 alkyl)$_2$, -C(=O)N(C_1-C_6 alkyl)(C_6-C_{10} aryl), -C(=O)O(C_1-C_6 alkyl), -C(=O)O(C_6-C_{10} aryl), -P(=O)(O(C_1-C_6 alkyl))$_2$, -P(=O)(O(C_1-C_6 alkyl))(OH), -P(=O)(OH)$_2$, -S(=O)$_2$O(C_6-C_{10} aryl), -S(=O)$_2$O(C_1-C_6 alkyl), -S(=O)$_2$O(C_6-C_{10} aryl), -S(=O)$_2$NH(C_1-C_6 alkyl), -S(=O)$_2$NH(C_6-C_{10} aryl), -S(=O)$_2$N(C_1-C_6 alkyl)(C_1-C_6 alkyl), and -S(=O)$_2$N(C_1-C_6 alkyl)(C_6-C_{10} aryl); and

each occurrence of R^B is independently selected from the group consisting of H, C_1-C_6 alkyl, C_1-C_3 haloalkyl, C_2-C_6 alkenyl, benzyl, naphthyl, C_2-C_9 heteroaryl, and phenyl.

21. The compound of claim 20, wherein at least one of the following applies:

(a) R^3 is H;

(b) each of R^8 and R^9 are independently selected from the group consisting of methyl, ethyl, *n*-propyl, *iso*-propyl, *sec*-butyl, *iso*-butyl, *n*-butyl, cyclopropyl, cyclopropylmethyl, methylcyclopropyl, cyclopropylethyl, cyclobutyl, allyl, methylallyl, 2-methylallyl, 3-methylallyl, allylmethyl, propargyl, cyanomethyl, 2-hydroxyethyl, and 2-methoxyethyl;

(c) R^{10} is H;

(d) each of R^{11} and R^{12} is H;

(e) R^{13} is H or methyl;

(f) each of R^{f1}, R^{f2}, R^{g1}, and R^{g2} is H.

22. The compound of claim 20 or 21, which is selected from the group consisting of:

N-ethyl-N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)propan-1-amine;

2-(7-fluoro-5-methoxy-1H-indol-3-yl)-N,N-dimethylethan-1-amine;

N,N-diethyl-2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethan-1-amine;

N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-propylpropan-1-amine;

3-(2-(dimethylamino)ethyl)-7-fluoro-1H-indol-5-ol;

3-(2-(diethylamino)ethyl)-7-fluoro-1H-indol-5-ol;

3-(2-(dipropylamino)ethyl)-7-fluoro-1H-indol-5-ol;

N-ethyl-2-(7-fluoro-5-methoxy-1H-indol-3-yl)-N-methylethan-1-amine;

N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-methylpropan-1-amine;

N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-methylpropan-2-amine;

N-ethyl-N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)propan-2-amine;

N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N,2-dimethylpropan-1-amine;

N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-methylcyclobutanamine;

N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-methylprop-2-en-1-amine;

N-(2-(7-fluoro-5-methoxy-1H-indol-3-yl)ethyl)-N-isopropyl-2-methylpropan-1-amine;

3-(2-(ethyl(methyl)amino)ethyl)-7-fluoro-1H-indol-5-ol;

7-fluoro-3-(2-(methyl(propyl)amino)ethyl)-1H-indol-5-ol;

7-fluoro-3-(2-(isopropyl(methyl)amino)ethyl)-1H-indol-5-ol;
3-(2-(ethyl(propyl)amino)ethyl)-7-fluoro-1H-indol-5-ol;
3-(2-(ethyl(isopropyl)amino)ethyl)-7-fluoro-1H-indol-5-ol;
7-fluoro-3-(2-(isobutyl(methyl)amino)ethyl)-1H-indol-5-ol;
3-(2-(cyclobutyl(methyl)amino)ethyl)-7-fluoro-1H-indol-5-ol;
3-(2-(allyl(methyl)amino)ethyl)-7-fluoro-1H-indol-5-ol;
7-fluoro-3-(2-(isobutyl(isopropyl)amino)ethyl)-1H-indol-5-ol;
3-(((2R)-1-(sec-butyl)pyrrolidin-2-yl)methyl)-7-fluoro-5-methoxy-1H-indole;
(R)-7-fluoro-3-((1-isopropylpyrrolidin-2-yl)methyl)-5-methoxy-1H-indole;
(R)-3-((1-cyclobutylpyrrolidin-2-yl)methyl)-7-fluoro-5-methoxy-1H-indole;
(R)-3-((1-cyclopropylpyrrolidin-2-yl)methyl)-7-fluoro-5-methoxy-1H-indole;
(R)-3-((1-allylpyrrolidin-2-yl)methyl)-7-fluoro-5-methoxy-1H-indole;
3-(((2R)-1-(but-3-en-2-yl)pyrrolidin-2-yl)methyl)-7-fluoro-5-methoxy-1H-indole; and
(R)-7-fluoro-5-methoxy-3-((1-(prop-2-yn-1-yl)pyrrolidin-2-yl)methyl)-1H-indole.

23. The compound of any one of claims 1-22, wherein each occurrence of alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl is independently optionally substituted with at least one substituent selected from the group consisting of C_1-C_6 alkyl, C_3-C_8 cycloalkyl, halo, cyano, OR^A, optionally substituted benzyl, optionally substituted phenyl, optionally substituted C_2-C_9 heteroaryl, $C(=O)OR^A$, $OC(=O)OR^A$, $OC(=O)R^A$, SR^A, $S(=O)R^A$, $S(=O)_2R^A$, $S(=O)_2N(R^A)(R^B)$, $N(R^A)S(=O)_2R^A$, $N(R^A)C(=O)R^A$, $C(=O)N(R^A)(R^B)$, and $N(R^A)(R^B)$.

24. The compound of any one of claims 1-23, wherein each occurrence of benzyl, phenyl, and heteroaryl is independently optionally substituted with at least one substituent selected from the group consisting of C_1-C_6 alkyl, C_3-C_8 cycloalkyl, halo, cyano, OR^A, $C(=O)OR^A$, $OC(=O)OR^A$, $OC(=O)R^A$, SR^A, $S(=O)R^A$, $S(=O)_2R^A$, $S(=O)_2N(R^A)(R^B)$, $N(R^A)S(=O)_2R^A$, $N(R^A)C(=O)R^A$, $C(=O)N(R^A)(R^B)$, and $N(R^A)(R^B)$.

25. A compound selected from the group consisting of:
N-(2-(5-fluoro-1H-indol-3-yl)ethyl)prop-2-en-1-amine;
2-(5-fluoro-1H-indol-3-yl)-N,N-dimethylpropan-1-amine;
N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-N-propylpropan-1-amine;

N,N-diethyl-2-(4-fluoro-1H-indol-3-yl)ethan-1-amine;
N-(2-(4-fluoro-1H-indol-3-yl)ethyl)-N-propylpropan-1-amine;
N-(2-(7-fluoro-1H-indol-3-yl)ethyl)-N-propylpropan-1-amine;
N-(2-(5,6-difluoro-1H-indol-3-yl)ethyl)-N-propylpropan-1-amine;
2-(5,7-difluoro-1H-indol-3-yl)-N,N-diethylethan-1-amine;
N-(2-(5,7-difluoro-1H-indol-3-yl)ethyl)-N-propylpropan-1-amine;
2-(6,7-difluoro-1H-indol-3-yl)-N,N-diethylethan-1-amine;
N-(2-(6,7-difluoro-1H-indol-3-yl)ethyl)-N-propylpropan-1-amine; and
2-(5-fluoro-1H-indol-3-yl)propan-1-amine.

26. A pharmaceutical composition comprising at least one compound of any one of claims 1-25 and a pharmaceutically acceptable carrier.

27. Use of the compound of any of claims 1-25, the compound of any of compounds **1-218**, or the pharmaceutical composition of claim 26 in the manufacture of a medicament for the treatment, prevention and/or amelioration of a psychiatric disease or disorder in a subject in need thereof, wherein a therapeutically effective amount of at least one compound of any of claims 1-25, at least one compound of any of compounds **1-218**, or the pharmaceutical composition of claim 26 is to be administered to the subject.

28. The use of claim 27, wherein the psychiatric disease or disorder is selected from the group consisting of a depressive disorder, anxiety disorder, and eating disorder.

29. The use of claim 27 or 28, wherein the psychiatric disease or disorder is selected from the group consisting of attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), treatment resistant depression, major depressive disorder (MDD), bipolar I disorder, bipolar II disorder, cyclothymic disorder, anti-social personality disorder, pain, sleep-wake disorders, disruptive mood dysregulation disorder, persistent depressive disorder (dysthymia), premenstrual dysphoric disorder, substance/medication-induced depressive disorder, post-partum depression, depressive disorder due to another medical condition, separation anxiety disorder, specific phobia, social anxiety disorder, panic disorder, panic attack, agoraphobia, generalized anxiety disorder, substance-medication induced anxiety disorder, anxiety disorder due to another medical condition, somatic symptom disorder,

illness anxiety disorder, obsessive-compulsive disorder (OCD), obsessive-compulsive and related disorder (OCRD), OCRD due to another medical condition, substance-related disorders, alcohol-related disorders, cannabis-related disorders, hallucinogen-related disorders, inhalant-related disorders, cocaine-related disorders, opioid-related disorders, sedative-, hypnotic-, and/or anxiolytic-related disorders, stimulant-related disorders, tobacco-related disorders, non-substance-related disorders (gambling and/or gaming disorder), anorexia nervosa, bulimia nervosa, and binge-eating disorder.

30. The use of any one of claims 27-29, wherein at least one additional agent useful for treating, preventing, and/or ameliorating the psychiatric disease or disorder is to be further administered to the subject.

31. The use of claim 30, wherein the at least one additional agent is selected from the group consisting of a selective serotonin reuptake inhibitor, triple reuptake inhibitor, serotonin and norepinephrine reuptake inhibitor, tricyclic antidepressant, tetracyclic antidepressant, dopamine reuptake inhibitor, mood stabilizer, anticonvulsant, antipsychotic, anxiolytics, benzodiazepines, monoamine releasers, dopamine receptor agonist, cannabinoids, triptans, anti-migraine medications, analgesics, anti-inflammatory, immune modulator, 5-HT_{1A} receptor antagonist, 5-HT_2 receptor antagonist, 5-HT_3 receptor antagonist, monoamine oxidase inhibitor, and noradrenergic antagonist.

32. The use of any one of claims 30-31, wherein the at least one compound and the at least one additional agent is to be co-administered to the subject, optionally wherein the at least one compound and the at least one additional agent are co-formulated.

33. The use of any one of claims 27-32, wherein the subject is a mammal, optionally wherein the mammal is a human.

34. The compound of any of claims 1-25, the compound of any of compounds **1**-**218**, or the pharmaceutical composition of claim 26, for use in therapy.